US-based biopharmaceutical company Dermira closed a $51m series C round yesterday that included pharmaceutical company UCB.
Also participating in the round were Bay City Capital, New Enterprise Associates, Canaan Partners, Apple Tree Partners, Aisling Capital, Rock Springs Capital, Sabby Capital and other, undisclosed healthcare investors.
Dermira develops dermatology products that include five product candidates, three of which are at a late stage of development. One of the candidates, Cimzia, is being developed in collaboration with UCB.
The company has now raised $128m across three rounds, including $35m from a series B round that featured Japan-based dermatology company Maruho.
Dermira also announced the appointment of four new board members, including Mark McDade, UCB’s as executive vice president for established brands, solutions and supply.